Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
IRVINE, Calif., Oct. 05, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq:ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the November 27, 2017 lead plaintiff motion deadline.
If you purchased Intercept shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. When this news was announced, shares of Intercept fell in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
